CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:

• Panel discussion at the Citi 9^th Annual Biotech Conference on Wednesday, September 3
• Presentation at the Morgan Stanley Global Healthcare Conference onMonday, September 8, at 8:45 a.m. Eastern Time

A live audio webcast of the Morgan Stanley presentation will be available on the Company's website at http://ir.akebia.com/events.cfm. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel, proprietary therapeutics to treat kidney disease. Akebia's lead clinical program, AKB-6548, is a once-daily, oral therapy currently in Phase 2b clinical development for the treatment of anemia related to chronic kidney disease, a serious medical condition that leads to increased morbidity and mortality if left untreated. For more information on Akebia, please visit www.akebia.com.

Investors:
Akebia Therapeutics
Nicole P. Jones, 617-871-1210
Senior Director, Investor Relations and Corporate Communications
njones@akebia.com
or
Media:
Feinstein Kean Healthcare
Liz Falcone, 617-761-6727
liz.falcone@fkhealth.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media